ASTRAL finds no benefit from renal stenting
The landmark ASTRAL trial, published in the NEJM this week, failed to demonstrate benefit from renal artery stenting in ‘most’ patients with atherosclerotic renal artery stenosis. ASTRAL was funded by the Medical Research Council UK, Kidney Research UK and Medtronic.
Research funded by the Medical Research Council UK, Kidney Research UK and Medtronic has concluded that revascularisation, a treatment which opens up blocked blood vessels, has no benefit for most patients suffering from the kidney condition atherosclerotic renal artery stenosis (ARAS).
Atherosclerotic renal artery stenosis is a disease of the arteries in which fatty plaques develop on the inside of the main arteries to the kidneys affecting blood flow and the ability of the kidneys to work properly.
The “Angioplasty and Stenting for Renal Artery Lesions” (ASTRAL) trial is the largest trial to date into treatment for the kidney condition, It considered whether there is any real benefit to a combined approach of revascularisation treatment and medical therapy, compared with just medical therapy alone.
More detail from Kidney Research UK website.
NEJM link to abstract and full paper.